Arno Therapeutics Reports First Quarter 2016 Financial and Business Update
May 16, 2016 16:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other...
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA®
April 19, 2016 08:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company dedicated to the development of therapeutics for cancer and...
Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update
March 30, 2016 16:16 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., March 30, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of therapeutics for cancer and other...
Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II
March 21, 2016 07:30 ET
|
Arno Therapeutics Inc.
- Phase II to include study of onapristone in combination with abiraterone - FLEMINGTON, N.J., March 21, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage...
Arno Therapeutics Completes $7.4 Million Common Stock Financing
January 13, 2016 07:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update
November 16, 2015 16:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J ., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis
October 29, 2015 07:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON N.J., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and...
Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
October 21, 2015 10:01 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and...
Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
September 25, 2015 06:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 25, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients With Serious Bacterial Infections
September 24, 2015 07:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...